Studies on the antigenicity of the NKG2D ligand H60a in tumour cells.
Studies on the antigenicity of the NKG2D ligand H60a in tumour cells.
复制标题
NKG2D配体H60a在肿瘤细胞中的抗原性研究。
DOI：
10.1111/j.1365-2567.2011.03427.x
复制
发表时间：
2011
期刊：
影响因子：
6.4
通讯作者：
Bui,JackD
中科院分区：
文献类型：
--
作者：
Yadav,Deepak;Ngolab,Jennifer;Dang,Natalie;Bui,JackD
H60 a是一种在BALB和129/Sv小鼠中表达的次要组织相容性抗原，但在C57 BL/6小鼠品系中不表达。C57 BL/6小鼠中的大多数CD 8 +T细胞对BALB有应答。B脾细胞对H60 a有特异性。有趣的是，H60 a在肿瘤细胞上组成型表达，但其作为肿瘤排斥抗原的性质，与其作为移植排斥抗原的功能相似，尚未研究。在这份报告中，我们表明在细胞表面组成型表达H60 a的肿瘤细胞可以被H60 a特异性T细胞识别。此外，当将表达H60 a的肉瘤细胞系移植到C57 BL/6小鼠中时，可以在肿瘤浸润性CD 8 +T细胞中以高百分比发现H60 a特异性T细胞。这些发现见于C57 BL/6小鼠，而非F1（C57 BL/6 × 129）小鼠（表达H60 a），表明内源性耐受机制抑制H60 a的抗原特性。 我们的研究结果对产生针对人类自然杀伤组2D配体的肿瘤疫苗具有意义，例如MHC I类链样基因A，它们也是移植抗原。
H60a is a minor histocompatibility antigen expressed in BALB and 129/Sv but not C57BL/6 mouse strains. The majority of CD8+T cells in C57BL/6 mice responding to BALB.B splenocytes are specific for H60a. Interestingly, H60a is expressed constitutively on tumour cells, but its nature as a tumour rejection antigen, as a parallel to its function as a transplant rejection antigen, has not been studied. In this report, we show that tumour cells that constitutively express H60a at the cell surface can be recognized by H60a‐specific T cells. Furthermore, when H60a‐expressing sarcoma cell lines are transplanted into C57BL/6 mice, H60a‐specific T cells can be found at high percentages among the tumour‐infiltrating CD8+T cells. These findings were seen in C57BL/6 but not F1 (C57BL/6 × 129) mice (which express H60a), suggesting that endogenous tolerance mechanisms suppress the antigenic properties of H60a. Our findings have implications for the generation of tumour vaccines against human natural killer group 2D ligands, such as MHC class I chain‐like gene A, that are also transplantation antigens.